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Abstract
BACKGROUND: Diabetic nephropathy (DN) is a chronic kidney disease with microvascular complications which 
influence a patient’s quality of life and poses a potentially significant economic burden. The discovery of new 
biomarkers is needed to gain a better understanding and find additional treatment approaches beyond controlling 
plasma glucose and blood pressure. The engulfment and cell motility protein called engulfment and cell motility 
protein (ELMO)-1 is known to play a role in tissue remodeling and is associated with DN progression in animal 
models. Human studies correlating this protein with DN have been limited, although a genetic variation of ELMO-1 
has been associated with DN.
AIMS: This research aimed to investigate the association and correlation of circulating ELMO-1 with the level of 
kidney damage in DN.
METHODS: The research design was cross-sectional. In this study, 60 patients with type 2 diabetes mellitus (T2DM) 
participated. Patients’ blood pressure, plasma glucose, and renal function parameters were measured to confirm 
the diagnosis. Albumin to creatinine ratio (ACR) was used to assess the level of kidney damage and determines 
DN group.
RESULTS: Analyses shown the severity of albuminuria which is associated with plasma ELMO-1 when DN is 
evident. Furthermore, in all study participants, plasma ELMO-1 was correlated with increased proteinuria, ACR, and 
decline of glomerular filtration rate.
CONCLUSIONS: Our research findings provide support for ELMO-1 as a promising marker of kidney damage level 
in patients with T2DM, especially when DN has occurred. Larger sample sizes and multicenter research in the 
Indonesian population are needed to confirm these results.
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Introduction
The incidence of diabetic nephropathy (DN) has 
increased worldwide, especially in Asian populations. 
This condition leads to end-stage renal diseases 
which often decrease a patient’s quality of life and 
cause potentially significant economic burden [1], [2]. 
Additional approaches are needed to prevent and treat 
DN beyond controlling hyperglycemia and high blood 
pressure. Research of new biomarkers is important 
to gain a better understanding of DN progression and 
further develop new treatment approaches to prevent 
the progression of DN [3], [4], [5].
Increased microalbuminuria and decreased 
glomerular filtration rate (GFR) are clinical markers of 
DN [6]. Tissue remodeling, including alteration of matrix 
deposition, podocytes, and endothelial injury, which 
increases cell apoptosis, may happen before clinical 
markers of DN are detected [7]. These events are 
associated with alteration of some circulating protein 
expressions, which are promising as new biomarkers 
before the commonly used clinical markers of DN 
appear [3], [7], [8].
The engulfment and cell motility protein called 
engulfment and cell motility protein (ELMO)-1 is known 
to play a role in tissue remodeling. The exact role of this 
protein in human DN pathophysiology is still unknown, 
although some genetic association studies reported 
that the ELMO-1 gene is a strong candidate as a DN 
associated gene. Polymorphism in the intronic region of 
ELMO-1 was associated with DN in Asia and America 
populations. None have described any association of 
its polymorphisms or DN with systemic or local ELMO-1 
expression, although translation studies in animal 
models have reported that the ELMO-1 protein does 
play a role in the progression of DN [9], [10], [11], [12].
Diabetic rat models which have different systemic 
levels of ELMO-1 shown higher ELMO-1 expression that 
was associated with severity of renal fibrosis and amount 
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of urinary albumin excretion through aggravated lipid 
peroxidation and increased tumor growth factor beta-1 
(TGFβ-1) levels, which are both markers of extracellular 
matrix expansion [13]. Another animal translation study 
that used a genetically modified zebrafish model shown 
that ELMO-1 is an important factor for glomerular 
protection and renal cell survival through decreasing 
apoptosis, especially under diabetic conditions [14].
This research was conducted because studies 
in humans about ELMO-1 expression in DN are limited, 
and recent findings in animal models briefly describe 
the promising potential of ELMO-1 as a new biomarker 
which plays a role in DN progression. This research 
aimed to investigate the association and correlation 
of circulating ELMO-1 in the progression of DN in the 
Indonesian population for the 1st time.
Materials and Methods
Study design
This research was a cross-sectional study. A 
total of 60 patients with type II diabetes mellitus (T2DM) 
were recruited from the Jambi province who fulfilled 
eligible criteria for this research. Inclusion criteria were as 
follows: Patient with T2DM who was suffering from DM 
for at least 5 years, with an age range of 30–60 years 
old. We excluded patients with urinary infections based 
on clinical examination and routine urine analysis, history 
of other kidney diseases based on the medical record, 
pregnant women, and immunocompromised subjects. 
Patients’ T2DM diagnosis was based on fasting plasma 
glucose >126 mg/dL and 2 h postprandial plasma glucose 
>200 mg/dL, as listed in medical records. In all patients, 
we measured albumin to creatinine ratio (ACR), GFR, 
and plasma creatinine as kidney function parameters 
and plasma ELMO-1. We also measured blood pressure 
and plasma glucose levels. All research subjects signed 
informed consent forms after receiving a detailed 
explanation about the study objectives and design. The 
research protocol was arranged based on the Helsinki 
Declaration and was approved by the research ethics 
committee of the Faculty of Medicine, Andalas University, 
with approval registration number 706/KEP/FK/2019.
Kidney function parameters
Random spot urine samples as much as 
30 mL were collected from the patients. Quantitative 
measurements of urine albumin were made with 
immunoturbidimetric. Urine creatinine was measured 
with enzymatic colorimetric. Then, the ACR was 
calculated based on the ratio of quantitative creatinine 
to albumin in random spot urine sampling. DN was 
diagnosed according to ACR, where DN was defined as 
ACR ≥30 mg/g. Furthermore, we also grouped degree of 
kidney damage level according to ACR, with normal to 
mildly albuminuria as the A1 group (ACR <30 mg/g), the 
moderately increased albuminuria as the A2 group (ACR 
30–300 mg/g), and the severely increased albuminuria 
as the A3 group (ACR >300 mg/g). GFR was calculated 
based on chronic kidney disease-epidemiology 
collaboration equation, based on estimated creatinine 
serum, gender equation coefficient, and age. Plasma 
creatinine levels were also measured with enzymatic 
colorimetric.
Measurement ELMO-1
Blood samples as much as 5 ml were 
collected from the antecubital vein. The centrifuge was 
performed within 30 min after collection and samples 
stored in −20°C before performing ELISA. Sandwich 
ELISA protocol for human ELMO-1 was used to 
measure ELMO-1 (MyBiosourceR) with catalog number 
MBS9321199. Random twice repetition of ELISA for 
some samples was used to confirm the results of ELISA.
Results
Baseline subject characteristics
Baseline subject characteristics are shown in 
Table 1. A total of 60 subjects who fulfilled the research 
inclusion criteria participated in this study, with 20 
subjects in each group.
Demographic characteristics shown that the 
mean age was younger in the A1 group than the other 
groups. Female subjects were more frequent in the A1 
and A2 groups, but it was not statistically significant.
We measured kidney function for each subject. 
The A1 group had lower urine creatinine, but it was not 
statistically significant. Lower plasma creatinine, urine 
albumin, ACR, and higher GFR were found in the A1 
group compared to the other groups, and the differences 
were statistically significant. These baseline subject 
characteristics shown that the A1 (non-ND) group had 
better kidney function than the A2 and A3 groups (ND).
All patients had been diagnosed with T2DM. 
The A1 group had lower fasting and postprandial plasma 
glucose than the A2 and A3 groups, but it was not 
statistically significant. Lower systolic and diastolic blood 
pressures were also found in the A1 group compared to 
the other groups, and the result was statistically significant.
Plasma ELMO-1 level was associated with 
the severity of kidney level damage based on ACR 
when DN occurs
The mean of ELMO-1 plasma level based on 
the grade of ACR is shown in Figure 1. ELMO-1 plasma 
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level for each group was not normally distributed even 
after transformation with log 10, so the non-parametric 
test was performed. The mean value of the ELMO-1 
plasma level of the A1 group was lower than the mean 
value of ELMO-1 plasma level of A2, but it was not 
statistically significant (p = 0.779). With the limited 
number of samples, this result has shown that ELMO-1 
was not associated with the level of kidney damage of 
microalbuminuria (A1 group) to early macroalbuminuria 
(A2 group).
Table 2: ELMO-1 level based on clinical characteristics affected 
by DN
Group parameter ELMO-1 level
Glomerular filtration rate
GFR ≥60 mL/min, n = 41 134.22 (29.10 – 3726.78)
GFR <60 mL/min, n 19 128.54 (61.77 – 3446.93)
Fasting plasma glucose
FPG ≤130 mg/dL, n = 25 121.44 (33.36 – 3446.93)
FPG >130 mg/dL, n = 35 134.22 (29.10 – 3726.78)
2 h postprandial plasma glucose
2 h pp ≤180 mg/dL, n = 9 144.16 (94.45 – 3131.57)
2 h pp >180 mg/dL, n = 51 128.54 (29.10 – 3726.78)
Blood pressure
SBP <140 mmHg and DBP <90 mmHg, n = 26 134.22 (29.10 – 1976.67)
SBP ≥140 mmHg and or DBP ≥90 mmHg, n = 34 126.41 (61.77 – 3726.78)
The mean value of ELMO-1 plasma level of 
A1 group was lower than the mean value of ELMO-1 
plasma level of A3, and it was statistically significant (p 
= 0.005). The mean value of ELMO-1 plasma level of 
the A2 group was lower than mean value of ELMO-1 
plasma level of the A3 group, and it was statistically 
significant (p = 0.009). This result shown that ELMO-1 
plasma level was associated with level of kidney 
damage based on ACR when DN has occurred (A2 and 
A3 groups were confirmed DN).
Table 3: Correlation of ELMO-1 with clinical parameter
Kidney function Serum ELMO-1 (ng/mL)
R p-value
Plasma creatinine, mg/dL 0.078 0.554
Urine creatinine, mg/dL ‒0.100 0.447
Urine albumin, mg/dL 0.344 0.007
Fasting plasma glucose, mg/dL 0.013 0.919*
Postprandial plasma glucose, mg/dL 0.110 0.403
Systolic blood pressure, mmHg 0.152 0.245
Diastolic blood pressure, mmHg 0.043 0.745
Glomerular filtration rate, mL/min ‒0.293 0.023*
Albumin creatinine ratio 0.383 0.003
Age, years old 0.197 0.132*
*Pearson correlation test was performed due to normally distributed data of one variable. Otherwise, the 
Spearman correlation was performed.
Table 2 shows that the mean value of ELMO-1 
plasma level was higher in variables affected by DN. 
Higher plasma ELMO-1 levels were found in the lower 
GFR group, in higher plasma glucose fasting and 2 h 
postprandial plasma glucose and higher blood pressure 
groups. Although plasma ELMO-1 level difference 
were not significant statistically between these 
groups.
Plasma ELMO-1 level was correlated with 
kidney function in all subjects with T2DM
That correlations of ELMO-1 with some clinical 
parameters which play a role in the progression of DN 
are shown in Table 3. Urine albumin and ACR have a 
positive weak correlation with ELMO-1 plasma level, 
and the result was statistically significant. GFR had a 
negative weak correlation with ELMO-1 plasma level, 
and the result was statistically significant.
Plasma creatinine, plasma glucose, blood 
pressure, and age had very weak positive correlations 
with ELMO-1 plasma level. Urine creatinine had a very 
weak negative correlation with ELMO-1 plasma level. 
This correlation was not statistically significant.
Discussion
DN, also known as diabetic kidney disease, 
causes structural changes and declining kidney 
function. Albuminuria and GFR are clinical markers 
widely used to monitor the progression of DN. Both 
markers are endpoints of many pathways, so prevention 
of decreases of the two markers is not easy. Identifying 
additional new markers which are directly involved in 
certain dominant pathways can assist in gaining better 
understanding of DN pathophysiology and help develop 
new approaches in DN treatment [3], [4], [5].
Analyses in our research shown the severity 
of albuminuria were associated with plasma ELMO-1 
when DN was evident (Figure 1). Furthermore, in all 
study, plasma ELMO-1 was correlated with declining 
of kidney function in patients with T2DM based on 
levels of proteinuria, ACR, and GFR (Table 2). This 
finding demonstrates that the ELMO-1 plasma level is 
Table 1: Baseline subject characteristic
Characteristic A1 (n = 20) A2 (n = 20) A3 (n = 20) p-value
Age and years old 48.05 ± 9.09 50.35 ± 7.36 51.95 ± 7.64 0.314**
Gender 0.619
Male, n 8 7 10
Female, n 12 13 10
Fasting plasma glucose, mg/dL 140.95 ± 35.49 154.80 ± 53.98 164.95 ± 57.69 0.513*
Postprandial plasma glucose, mg/dL 242.7 ± 96.09 224.55 ± 50.66 257.10 ± 57.79 0.321*
Systolic blood pressure, mmHg 120.00 (100.00 – 160.00) 130.00 (110.00 – 150.00) 150.00 (110.00 – 170.00) <0.001**
Diastolic blood pressure, mmHg 80.00 (50.00 – 90.00) 80.00 (60.00 – 90.00) 80.00 (70.00 – 100.00) 0.042**
Plasma creatinine, mg/dL 0.88 ± 0.38 0.90 ± 0.22 1.92 ± 1.06 0.001*
Urine creatinine, mg/dL 86.21 (13.43 – 377.97) 114.04 (19.69 – 351.55) 79.31 (11.43 – 192.99) 0.217**
Urine albumin, mg/dL 14.7 ± 10.77 89.25 ± 83.71 2015.80 ± 2755.93 <0.001*
Albumin creatinine ratio 12.82 (4.06  –  28.44) 47.36 (30.68  –  203.77) 2263.00 (349.96 – 14403.00) <0.001**
Glomerular filtration rat, mL/min 92.66 ± 23.59 84.17 ± 22.55 50.34 ± 37.10 <0.001*
*One-way ANOVA was performed due to normally distributed data. **Non-parametric test was performed due to not normally distributed data even after transformation with log 10.
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a promising biomarker of the severity level of kidney 
damage in DN in the Indonesia population. In addition, 
ELMO-1 plasma level is also a promising marker of 
declining kidney function in patients with T2DM.
Figure 1: Mean of engulfment and cell motility protein-1 plasma level 
based on the grade of albumin to creatinine ratio
Studies of ELMO-1 plasma or tissue specifically 
associated with diabetes or DN in humans are still 
limited. One study found kidney expression of ELMO-1 in 
the non-diabetic compared to diabetic patient remained 
unchanged in podocytes and tubules, but it did not 
define whether the diabetic patient was suffering DN or 
not [14]. Phenotype genotype association studies have 
shown that the ELMO-1 gene is a strong gene candidate 
associated with DN. Single nucleotide polymorphism 
in the intronic region of ELMO-1 gene was associated 
with DN in Asia and American populations, but none 
described the correlation with systemic or local ELMO-1 
expression [9], [10], [11], [12].
One supporting study about the role of 
ELMO-1 related to DN described the association using 
an animal model. Using a zebrafish animal model, 
the results shown that ELMO-1 knockout model has 
a more detrimental effect on pronephric structure and 
function under hyperglycemia conditions compared 
to controls. This finding related to the detrimental 
effect on the processes of podocytes and glomerular 
ultrafiltration. Injection of ELMO-1 mRNA to create 
ELMO-1 overexpression and pan-caspase inhibitor 
rescue altered the renal structure and function. This 
research shown that ELMO-1 was an important 
factor for glomerular protection and renal cell survival 
that decreasing apoptosis, especially under diabetic 
conditions [14]. Another study found that a rat model 
with a mutation of in insulin-2 gene had different levels 
of ElMO-1. The research reported that higher ELMO-1 
expression was associated with the severity of renal 
fibrosis and amount of urinary albumin excretion. The 
increased expression of ELMO-1 was followed by the 
aggravated marker of oxidative stress and NAD(P)H 
oxidase 4 and reduced glutathione, and the aggravated 
markers of fibrogenesis, TGFβ-1, and endothelin-1 [13].
Baseline subject characteristics shown that 
blood mean systolic and diastolic blood pressures 
were associated with the degree of albuminuria, but 
plasma glucose was not, although lower plasma 
glucose was found in the A1 group compared to the A2 
and A3 groups. The previous study shown controlling 
glucose plasma and blood pressure influences the 
progression of DN, although the duration of diabetes 
also contributes to DN [2], [6], [7]. Age and gender 
were not confounding factors for this research, and in 
the baseline characteristics, it did not differ statistically 
between the three groups.
Random spot urine sampling for ACR is 
used as one of the markers of DN progression. In this 
research, we used this marker as a reference to know 
DN progression because a previous study reported 
that it was representative and more practical to assess 
proteinuria related to diabetic complications than 24-h 
urine samples. In the next step, we grouped ACR into 
three groups. There were A1 or mildly albuminuria, A2 
or moderately increased or microalbuminuria, and A3 
or severe increased or macro-albuminuria. DN was 
confirmed and diagnosed with ACR in groups A2 and 
A3 [7], [15]. To the best of our knowledge, this is the 
first study of the association of circulating ELMO-1 with 
DN in the Indonesia population. Some limitations of our 
study were that it was conducted in only one center and 
had a limited number of participants which reduced the 
generalizability of the findings. To confirm the finding 
of ELMO-1 as a progression marker of severity in 
DN, further multicenter studies with larger numbers of 
participants are needed.
Conclusions
Plasma ELMO-1 level is associated with the 
severity level of kidney damage based on ACR when 
DN has occurred. Albuminuria and ACR had positive 
correlations with plasma ELMO-1 and GFR had a 
negative correlation with plasma ELMO-1 in all subjects 
who suffered T2DM. These findings shown that plasma 
ELMO-1 is a promising marker of the level of kidney 
damage, especially when DN has occurred in the 
Indonesia population. According to the limitations of 
this study, larger numbers of subjects and multicenter 
research are needed.
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